(Q37671920)

21 August 2017

1 reference

title

Mechanisms of resistance to HER family targeting antibodies (English)

1 reference

21 August 2017

1 reference

Tim J Kruser

1

1 reference

ORCID Public Data File 2021

author name string

Deric L Wheeler

series ordinal

2

1 reference

PubMed ID

20064507

21 August 2017

language of work or name

English

0 references

publication date

11 January 2010

1 reference

Experimental Cell Research

21 August 2017

1 reference

21 August 2017

316

1 reference

21 August 2017

7

1 reference

21 August 2017

1083-1100

1 reference

Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis

21 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

"Oncogenic shock": explaining oncogene addiction through differential signal attenuation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Untangling the ErbB signalling network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

ERBB receptors and cancer: the complexity of targeted inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Signal transduction and oncogenesis by ErbB/HER receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Localization of epidermal growth factor receptor in hepatocyte nuclei

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Functional nuclear epidermal growth factor receptors in human choriocarcinoma JEG-3 cells and normal human placenta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Nuclear localization of EGF receptor and its potential new role as a transcription factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Co-regulation of B-Myb expression by E2F1 and EGF receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Characterization of a novel tripartite nuclear localization sequence in the EGFR family.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Role of the Sec61 translocon in EGF receptor trafficking to the nucleus and gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Correlates and determinants of nuclear epidermal growth factor receptor content in an oropharyngeal cancer tissue microarray

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Cetuximab for the treatment of colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Platinum-based chemotherapy plus cetuximab in head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Copy number gains on 22q13 in adenoid cystic carcinoma of the salivary gland revealed by comparative genomic hybridization and tissue microarray analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Tissue Microarray Analysis of C-MYC Oncogene Copy Number Changes in Larynx Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Association of epidermal growth factor receptor (EGFR) gene copy number amplification with neck lymph node metastasis in areca-associated oral carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

A prospective study of dietary folate and vitamin B and colon cancer according to microsatellite instability and KRAS mutational status.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Tyrosine phosphorylation controls PCNA function through protein stability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Nuclear EGFR contributes to acquired resistance to cetuximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Humanization of an anti-p185HER2 antibody for human cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

TGFalpha expression impairs Trastuzumab-induced HER2 downregulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2010.01.009

10.1016/J.YEXCR.2010.01.009

7 January 2021

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

20064507